Free Trial
NASDAQ:EKSO

Ekso Bionics Q2 2025 Earnings Report

Ekso Bionics logo
$3.38 -0.07 (-2.03%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.42 +0.04 (+1.33%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ekso Bionics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.20
Beat/Miss
N/A
One Year Ago EPS
N/A

Ekso Bionics Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.31 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ekso Bionics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, July 28, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Ekso Bionics Earnings Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Ekso Bionics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ekso Bionics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ekso Bionics and other key companies, straight to your email.

About Ekso Bionics

Ekso Bionics (NASDAQ:EKSO) is a leader in wearable robotics technology, specializing in powered exoskeletons designed to augment human strength, endurance and mobility. Founded in 2005 as Berkeley Bionics and rebranded in 2015, the company has pioneered a range of exoskeletal solutions that address both medical rehabilitation and industrial workforce support. Headquartered in Richmond, California, Ekso Bionics combines robotic engineering with clinical research to provide products that enhance patient outcomes and promote safer work environments.

The company operates two main business segments: Ekso Health and Ekso Works. Ekso Health offers a portfolio of FDA-cleared exoskeletons and neurorehabilitation devices, including models for gait training in patients recovering from stroke, spinal cord injury and other neurological impairments. Hospitals, rehabilitation centers and research institutions leverage these devices to accelerate functional recovery, improve patient engagement and collect objective performance data to guide therapy.

Under the Ekso Works banner, the company develops industrial-strength exoskeletons that reduce the risk of musculoskeletal injury and fatigue among workers engaged in repetitive or physically demanding tasks. These wearable systems are deployed in manufacturing, warehousing, construction and logistics settings, where they help lift heavy objects, maintain proper posture and increase overall productivity. Partnerships with global corporations and pilot programs in Europe, Asia and North America demonstrate the technology’s adaptability to diverse operational needs.

Over its history, Ekso Bionics has cultivated a multidisciplinary team of engineers, clinicians and researchers led by Chief Executive Officer Nathan J. Harding. The company maintains sales and service networks across major global markets, collaborating with academic institutions, healthcare providers and industrial partners to refine its products and expand adoption. With a focus on innovation and evidence-based outcomes, Ekso Bionics continues to advance the practical application of robotic exoskeletons.

View Ekso Bionics Profile

More Earnings Resources from MarketBeat